6533b827fe1ef96bd12870b6

RESEARCH PRODUCT

Therapeutic-like properties of a dopamine uptake inhibitor in animal models of amphetamine addiction.

Juan J. CanalesJaime Renau-piquerasClara Velázquez-sánchezAntonio Ferragud

subject

Malemedicine.medical_treatmentmedia_common.quotation_subjectAmphetamine-Related DisordersSelf AdministrationNucleus accumbensPharmacologyMotor ActivityNucleus AccumbensMiceDopamine Uptake InhibitorsRewardDopamineConditioning PsychologicalmedicineAnimalsPharmacology (medical)Amphetaminemedia_commonDopamine transporterPharmacologyBenztropineDopamine Plasma Membrane Transport ProteinsbiologyBehavior AnimalAddictionBenztropineConditioned place preferenceRatsStimulantPsychiatry and Mental healthAmphetamineDisease Models Animalbiology.proteinPsychologymedicine.drug

description

N-substituted benztropine (BZT) analogs are molecules that display high affinity for the dopamine transporter (DAT), therapeutic-like effects in animal models of cocaine abuse, and psychopharmacological characteristics consistent with those of a substitute medication for cocaine addiction. Since amphetamine (Amph) and cocaine share mechanisms of action at the DAT, we evaluated the effectiveness of a BZT analog in animal models of Amph addiction. We tested in mice and rats the effects of the BZT derivative, 3α-[bis(4-fluorophenyl)methoxy]-tropane (AHN-1055), on Amph-induced conditioned place preference (CPP), locomotor activity, sensitization, self-administration and ΔFosB accumulation in the nucleus accumbens (NAc). The results showed that AHN-1055 did not produce rewarding, stimulant, or sensitized locomotor effects in mice when administered alone but it readily blocked the rewarding, stimulant, and sensitizing effects of repeated Amph exposure. Furthermore, in mice undergoing conditioning in the CPP paradigm, the BZT analog prevented the accumulation of ΔFosB protein induced in the NAc shell region by Amph treatment. Notably, treatment with AHN-1055 dose-dependently reduced Amph self-administration in rats with a steady history of voluntary Amph intake. These results provide a straightforward demonstration that a BZT derivative with binding affinity for DAT exhibits high efficacy in animal models of Amph abuse, suggesting that the novel generation of BZT analogs could have wider therapeutic applications in stimulant-spectrum disorders than those previously recognized.

10.1017/s1461145710000969https://pubmed.ncbi.nlm.nih.gov/20735880